血清IL-34联合超声弹性成像诊断慢性乙型肝炎患者肝纤维化的效能分析

doi:10.3969/j.issn.1672-5069.2021.01.007

摘要/Abstract

摘要： 目的研究应用血清IL-34和肝脏硬度检测(LSM)诊断慢性乙型肝炎(CHB)患者肝纤维化的效能。方法 2018年6月～2019年6月我院接受经皮肝穿刺活检的CHB患者100例,采用ELISA法检测血清IL-34和血清 HBsAg水平,采用实时荧光定量PCR法检测血清HBV DNA,使用雅培公司生产的全自动生物化学分析仪检测血生化指标,计算谷草转氨酶(AST)/血小板(PLT)比率指数(APRI)和肝纤维化-4因子指数(FIB-4)评分,使用FibroTouch检测LSM,采用单因素和多因素Logistic回归分析影响CHB患者显著性肝纤维化的独立预测因素,应用受试者工作特征(ROC)曲线下面积(AUC)分析CHB患者显著肝纤维化发生的独立影响因素。结果经肝组织学检查,诊断肝纤维化F0/F1期(非显著性肝纤维化)组32例,>F2(显著性肝纤维化)组68例。非显著性肝纤维化组年龄为(35.2±8.0)岁,显著小于显著性肝纤维化组,血清IL-34水平为(10.8±3.6)pg/ml,显著低于显著性肝纤维化组,LSM为(6.1±1.4)kPa,显著小于显著组,APRI评分为(0.5±0.2),显著低于显著组,FIB-4评分为(1.2±1.0),显著低于显著组;多因素Logistic回归分析发现血清IL-34、LSM、APRI和FIB-4是影响CHB患者发生显著性肝纤维化的独立影响因素(P<0.05);血清IL-34、LSM、APRI 和FIB-4诊断显著性肝纤维化的AUC分别为0.84、0.89、0.74和0.72,当联合应用IL-34和LSM诊断显著性肝纤维化时,其AUC、敏感度和特异度分别为0.92、89.4%和94.0%。结论应用血清IL-34和LSM联合诊断CHB患者显著性肝纤维化的效能较为理想,值得进一步研究。

关键词: 慢性乙型肝炎, 肝纤维化, IL-34, 超声弹性成像, Logistic回归分析, 诊断

Abstract: Objective The aim of this study was to investigate the diagnostic efficacy of serum IL-34 level and transient elastography in predicting liver fibrosis in patients with chronic hepatitis B (CHB). Methods A total of 100 patients with CHB underwent percutaneous liver biopsies in our hospital from June 2018 through June 2019. Serum IL-34 levels were detected by ELISA and the liver stiffness measure (LSM) were obtained by elastography. The asparate aminotransferase/platelet ratio index (APRI) and the liver fibrosis -4 factor index (FIB-4) were calculated. The univariate and multivariate Logistic regression analysis were performed to determine the independent predictors of significant liver fibrosis in patients with CHB. The receiver operating characteristic (ROC) curve was used to analyze the cutoff value of independent predictors, and the area under the curve (AUC), diagnostic sensitivity (Se) and specificity (Sp) were calculated. Results Out of 100 patients with CHB, the liver histopathological examination showed fibrosis 0 (F0) in 7 cases, F1 in 25 (non-significant liver fibrosis in 32), and F2 in 32, F3 in 28 and F4in 8 cases (>F2 as significant liver firobosis in 68); the age in non-significant liver fibrosis was (35.2±8.0)yr, much younger than , serum IL-34 level was (10.8±3.6)pg/ml, much lower than , the LSM was (6.1±1.4)kPa, much lower than , the APRI score was (0.5±0.2), much lower than and the FIB-4 score was (1.2±1.0), much lower than in patients with significant liver fibrosis; the multivariate Logistic regression analysis showed that serum IL-34 levels, the LSM, the APRI and FIB-4 scores were the independent factors affecting liver fibrosis (P<0.05); the AUC in diagnosing liver fibrosis by serum IL-34 levels, the LSM, the APRI and FIB-4 scores were 0.84, 0.89, 0.74 and 0.72, and the AUC, the Se and Sp by serum IL-34 and LSM combination were 0.92, 89.4% and 94.0%, respectively.Conclusion The application of serum IL-34 levels might be used as an efficacious index for the diagnosis of liver fibrosis in patients with CHB, and its combination with LSM could improve the diagnostic efficacy.

Key words: Hepatitis B, Interleukin-34, Liver stiffness measurement, Logistic regression analysis, Diagnosis

吴冬秋, 崔丽华, 熊峰, 邬政宏. 血清IL-34联合超声弹性成像诊断慢性乙型肝炎患者肝纤维化的效能分析[J]. 实用肝脏病杂志, 2021, 24(1): 23-26.

Wu Dongqiu,Cui Lihua,Xiong Feng,et al. Diagnostic efficacy of serum IL-34 level and transient elastography in predicting liver fibrosis in patients with chronic hepatitis B[J]. Journal of Practical Hepatology, 2021, 24(1): 23-26.

参考文献

[1] Trembling PM, Lampertico P, Parkes J, et al. Performance of enhanced liver fibrosis test and comparison with transient elastography in the identification of liver fibrosis in patients with chronic hepatitis B infection. J Viral Hepat, 2014, 21(6):430-438.
[2] Lee HW, Yoo EJ, Kim BK, et al. Prediction of development of liver-related events by transient elastography in hepatitis B patients with complete virological response on antiviral therapy. Am J Gastroenterol, 2014, 109(8):1241-1249.
[3] Gomez-Moreno AZ, Pineda-Tenor D, Jimenez-Sousa MA, et al. Liver stiffness measurement predicts liver-related events in patients with chronic hepatitis C: A retrospective study. PLoS One, 2017, 12(9):e0184404.
[4] Preisser L, Miot C, Le Guillou-Guillemette H, et al. IL-34 and macrophage colony-stimulating factor are overexpressed in hepatitis C virus fibrosis and induce profibrotic macrophages that promote collagen synthesis by hepatic stellate cells. Hepatology, 2014, 60: 1879-1890.
[5] Tacke F. Functional role of intrahepatic monocytesubsets for the progression of liver inflammation and liver fibrosis in vivo. Fibrogenesis Tissue Repair, 2012, 5: S27.
[6] Hume DA, MacDonald KP. Therapeutic applications of macrophage colony-stimulating factor-1 (CSF-1) and antagonists of CSF-1 receptor (CSF-1R) signaling. Blood, 2012, 119: 1810-1820.
[7] Shoji H, Yoshio S, Mano Y, et al. Interleukin-34 as a fibroblast-derived marker of liver fibrosis in patients with non-alcoholic fatty liver disease. Sci Rep, 2016, 6: 28814.
[8] European Association for the Studyof the Liver; European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol, 2017, 67: 370-398.
[9] Afdhal NH. Biopsy or biomarkers: is there a gold standard for diagnosis of liver fibrosis? Clin Chem, 2004, 50: 1299-1300.
[10] Sharma S, Khalili K, Nguyen GC. Non-invasive diagnosis of advanced fibrosis and cirrhosis. World J Gastroenterol, 2014, 20: 16820-16830.
[11] Castera L. Noninvasive methods to assess liver disease in patients with hepatitis B or C. Gastroenterology, 2012, 142: 1293-1302.
[12] Degos F, Perez P, Roche B, et al. FIBROSTIC study group. Diagnostic accuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic viral hepatitis: a multicenter prospective study (the FIBROSTIC study). J Hepatol, 2010, 53: 1013-1021.
[13] 中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2015 年版). 实用肝脏病杂志, 2016, 19(3):389-400.
[14] Chon YE, Choi EH, Song KJ, et al. Performance of transient elastography for the staging of liver fibrosis in patients with chronic hepatitis B: a meta-analysis. PLoS One, 2012, 7: e44930.
[15] Xiao H, Shi M, Xie Y, et al. Comparison of diagnostic accuracy of magnetic resonance elastography and Fibroscan for detecting liver fibrosis in chronic hepatitis B patients: A systematic review and meta-analysis. PLoS One, 2017, 12(11):e0186660.
[16] Ding D, Li H, Liu P, et al. FibroScan, aspartate aminotransferase and alanine aminotransferase ratio (AAR), aspartate aminotransferase to platelet ratio index (APRI), fibrosis index based on the 4 factor (FIB-4), and their combinations in the assessment of liver fibrosis in patients with hepatitis B. Int J Clin Exp Med, 2015, 8(11):20876-20882.
[17] Jia J, Hou J, Ding H, et al. Transient elastography compared to serum markers to predict liver fibrosis ina cohort of Chinese patients with chronic hepatitis B. J Gastroenterol Hepatol, 2015, 30(4):756-762.
[18] Goyal R, Mallick SR, Mahanta M, et a1. Fibroscan can avoid liver biopsy in Indian patients with chronic hepatitis B. J Gastroenterol Hepatol, 2013, 28(11): 1738-1745.
[19] Liu XD, Wu JL, Liang J, et al. Globuljn-platelet model predicts minimal fibrosis and cirrhosis in chronic hepatitis B virus infected patients. World J Gastroenterol, 2012, 18(22):2784-2792.